Posted by Michael Wonder on 11 Mar 2024
Praluent (alirocumab) injection receives FDA approval to treat children with genetic form of high cholesterol
11 March 2024 - Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolaemia.
Regeneron Pharmaceuticals announced the US FDA has extended the approval of Praluent (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol lowering therapies to include paediatric patients aged 8 and older with heterozygous familial hypercholesterolaemia.
